Back

A dramatic impairment of the antitumor activity of human Vgamma9Vdelta2 T cells is induced by TGF-beta through significant phenotype, transcriptomic and metabolic changes

RAFIA, C.; LOIZEAU, C.; RENOULT, O.; HARLY, C.; PECQUEUR, C.; JOALLAND, N.; SCOTET, E.

2022-09-23 immunology
10.1101/2022.09.22.509026 bioRxiv
Show abstract

Despite significant advances, the eradication of cancer remains a clinical challenge which justifies the urgent exploration of additional therapeutic strategies such as immunotherapies. Human peripheral V{gamma}9V{delta}2 T cells represent an attractive candidate subset for designing safe, feasible and effective adoptive T cell transfer-based therapies. However, following their infiltration within tumors, {gamma}{delta} T cells are exposed to various regulating constituents and signals from the tumor microenvironment (TME), which severely alter their antitumor functions. Here, we show that TGF-{beta}, whose elevated production in some solid tumors is linked to a poor prognosis, interferes with the antigenic activation of human V{gamma}9V{delta}2 T cells in vitro. This regulatory cytokine strongly impairs their cytolytic activity, which is accompanied by the induction of particular phenotypic, transcriptomic and metabolic changes. Collectively, these observations provide informations for better understanding and targeting the impact of TME components to regulate the antitumor activity of human T cell effectors.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Cellular & Molecular Immunology
14 papers in training set
Top 0.1%
26.9%
2
Frontiers in Immunology
586 papers in training set
Top 0.2%
15.3%
3
eLife
5422 papers in training set
Top 16%
5.0%
4
Cell Discovery
54 papers in training set
Top 1%
4.5%
50% of probability mass above
5
Cancer Immunology Research
34 papers in training set
Top 0.1%
3.7%
6
Signal Transduction and Targeted Therapy
29 papers in training set
Top 0.4%
3.2%
7
Cell Reports Medicine
140 papers in training set
Top 2%
3.2%
8
Theranostics
33 papers in training set
Top 0.3%
2.7%
9
iScience
1063 papers in training set
Top 11%
2.0%
10
Advanced Science
249 papers in training set
Top 9%
2.0%
11
European Journal of Immunology
57 papers in training set
Top 0.3%
1.5%
12
Cell Reports
1338 papers in training set
Top 26%
1.4%
13
Nature Communications
4913 papers in training set
Top 59%
0.9%
14
Protein & Cell
25 papers in training set
Top 2%
0.9%
15
Acta Pharmaceutica Sinica B
11 papers in training set
Top 0.8%
0.8%
16
International Journal of Molecular Sciences
453 papers in training set
Top 14%
0.8%
17
PLOS Pathogens
721 papers in training set
Top 8%
0.8%
18
PLOS Biology
408 papers in training set
Top 20%
0.7%
19
Allergy
23 papers in training set
Top 0.7%
0.7%
20
Journal of Experimental Medicine
106 papers in training set
Top 4%
0.7%
21
Cells
232 papers in training set
Top 7%
0.7%
22
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 10%
0.7%
23
Cell Communication and Signaling
35 papers in training set
Top 1%
0.7%
24
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 1%
0.7%
25
mBio
750 papers in training set
Top 12%
0.7%
26
Frontiers in Oncology
95 papers in training set
Top 4%
0.7%
27
National Science Review
22 papers in training set
Top 3%
0.7%
28
PLOS ONE
4510 papers in training set
Top 73%
0.5%
29
The Journal of Immunology
146 papers in training set
Top 2%
0.5%
30
Scientific Reports
3102 papers in training set
Top 80%
0.5%